and insert therefor the following formula:

REMARKS

Claims 1-11 are now in the application, of which claim 1 is generic. The indication of the allowability of claims 2 and 7 is hereby noted.

The rejection of claim 1 and the objection to the specification at page 1, concerning the numbering (1" and 4") of the pyran ring have been overcome by this amendment to the specification and to claim 1.

The title has been amended as requested. Moreover, the application has been amended to include an abstract as required.

The rejection of claim 1 under the first paragraph of 35 U.S.C. 112 as being based on a disclosure non-enabling

with respect to the breadth of the claim in reciting that R_2 can be hydrogen is not deemed tenable. In particular, the specification adequately teaches the preparation of a compound wherein R_2 is a hydrogen atom. Along these lines see Example 1 on page 7 of the specification, which discloses, N-methyl-11-aza-10-deoxo-10-dihydro erythromycin A, wherein R_2 stands for a hydrogen atom. Also, see page 2, lines 2, 30, and 33 of the specification. The last paragraph on page 2 of the specification also clearly supports the recitation of R_2 being hydrogen and suggests how to make such.

The rejection of claims 3-6 and 8-11 under the second paragraph of 35 U.S.C. 112 based on the position that the compounds as presently named, will not have the oxygen atoms attached to the rings, is not deemed tenable since the recitation "erythromycin A" denotes the presence of oxygen atoms attached to the rings as required.

Reconsideration and allowance are respectfully solicited.

If the Examiner thinks that an interview might serve to advance the prosecution of this case in any way, the undersigned attorney is available at the telephone number noted below.

Burton A. Amernia Reg. No. 24,852

Attorney for Applicants 331-7111

Respectfully submitted,

Pollock, Vande Sande & Priddy 1990 M Street, N.W., Suite 800 P.O. Box 19088 Washington, D.C. 20036

Date: 4-19-83